Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Semaglutide and Cagrilintide Co-formulation vs Separate Injections
NCT05046873Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2021
- Primary completion
- Jan 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cagrilintide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the semaglutide plasma concentration-time curve from time 0 to infinity and Area under the NNC0480-0389 plasma concentration-time curve from time 0 to infinity. Started Sep 2021; status: completed.
02
Drugs
cagrilintide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05046873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05046873.